Life Science REIT PLC
Life Science REIT PLC owns and operates residential properties focused on the life sciences sector, generating income primarily through property rentals and long-term leases.
Business. Life Science REIT PLC (LABS.L) is a real estate investment trust primarily engaged in the residential real estate sector. The company generates revenue through rental income and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic presence are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Life Science REIT PLC (LABS.L) is a real estate investment trust primarily engaged in the residential real estate sector. The company generates revenue through rental income and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic presence are not provided in the available data.
Life Science REIT PLC maintains a debt-to-equity ratio of 0.38, indicating a relatively conservative capital structure with equity significantly outweighing liabilities. The company's liquidity position is assessed as medium, with cash and equivalents amounting to £14.34 million, which is lower than its long-term debt of £107.92 million. This suggests potential pressure to manage short-term obligations, particularly as net cash is negative after subtracting total debt.
Profitability metrics are not explicitly provided, but the company's operating cash flow of £7.62 million indicates a positive cash-generating ability. However, capital expenditures of £24.03 million suggest significant reinvestment in the property portfolio, which may impact near-term free cash flow. The company's debt-to-equity ratio is below the median for the Residential REITs industry, suggesting a more stable capital structure compared to peers.
The company's revenue is concentrated in the residential life sciences sector, with no disclosed geographic diversification. This concentration may expose the company to sector-specific risks, such as regulatory changes or shifts in demand for life science residential properties. No specific segments are disclosed, but the company's operations are primarily focused on property ownership and management.
The company's revenue for the latest period was £19.94 million, with an analyst-estimated revenue of £23.99 million. The growth trajectory is not explicitly outlined, but the capital expenditures suggest ongoing investment in the property portfolio. The company's EPS was reported at £0.02, indicating a modest earnings per share.
Risk factors include medium liquidity risk due to the company's cash position relative to its debt obligations. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's ESG scores indicate moderate governance and social performance, with a high ESG controversies score suggesting potential reputational risks.
Recent events include the latest financial filing, which disclosed the company's revenue, liabilities, and equity. No recent transcripts or filings beyond the financial snapshot are available for analysis.
- Life Science REIT PLC maintains a conservative capital structure with a debt-to-equity ratio of 0.38.
- The company's liquidity position is medium, with cash and equivalents lower than long-term debt.
- Revenue is concentrated in the residential life sciences sector, with no disclosed geographic diversification.
- The company's ESG scores indicate moderate governance and social performance, but a high controversies score suggests potential reputational risks.
- Capital expenditures of £24.03 million indicate ongoing investment in the property portfolio.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Life Science REIT PLC Market data — financials · 2026-05-28
- Life Science REIT PLC Market data — analyst estimates · 2026-05-28
- Life Science REIT PLC Market data — ESG · 2026-05-28